Back to discover
Drug

Vinblastine

Approved medicine
ResearchActive indication expansion
Also known as VLB, Vincaleukoblastine, Vinblastin, Vinblastina+2 more

VLB, Vincaleukoblastine, Vinblastin, Vinblastina, VinBLAStine Sulfate, Vinblastinum.

RxNorm11198ChEMBLCHEMBL159ATCL01CA01UNII5V9KLZ54CY
3
Research papers
31
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer

Clinical trial2026-08-31Primary completion · ClinicalTrials.gov

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Clinical trial2026-08-11Results expected Q2 2031 · ClinicalTrials.gov

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

Clinical trial2026-08-04Results expected Q3 2027 · ClinicalTrials.gov

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Clinical trial2026-08-04Results posted · ClinicalTrials.gov

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Clinical trial2026-07-31Primary completion · ClinicalTrials.gov

A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma

Clinical trial2026-07-09Results expected Q1 2032 · ClinicalTrials.gov

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Clinical trial2026-07-08Results expected Q3 2030 · ClinicalTrials.gov

A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Clinical trial2026-07-02Results expected Q4 2026 · ClinicalTrials.gov

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Clinical trial2026-06-17Results expected Q1 2027 · ClinicalTrials.gov

Estimating the global burden of Epstein-Barr virus-related cancers.

Research2021-10-27Journal of cancer research and clinical oncology

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Research2017-02-17The New England journal of medicine

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Research2003-08-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Vinblastine
Aliases & brands
VLBVincaleukoblastineVinblastinVinblastinaVinBLAStine SulfateVinblastinum
RxNorm CUI
11198
ChEMBL ID
CHEMBL159
ATC codes
L01CA01
UNII
5V9KLZ54CY

Clinical trials

144 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
144
registered trials across all phases
LATEST COMPLETION 2026
31
Active studies
14
Recruiting
57
Late-stage (III+)
78
Completed
35
Discontinued
PHASE DISTRIBUTIONn = 144
Early Phase 12Phase 19Phase 1 / 27Phase 269Phase 2 / 33Phase 346Phase 43Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine in Indian Patients With Untreated Stage 3/4 Classical Hodgkin Lymphoma

RecruitingPH IVTakedan=1242028

First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents

CompletedPH IVChristine Mauz-Körholzn=2252023

Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

CompletedPH IVBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladeshn=602018

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

RecruitingPH IIIKey trialUniversity College, Londonn=1,0422032

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

RecruitingPH IIIKey trialNational Cancer Institute (NCI)n=1,8752031

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

CompletedN/AMemorial Sloan Kettering Cancer Centern=1182026

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

CompletedPH IIIKey trialTakedan=1,3342026

A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)

CompletedPH IIFox Chase Cancer Centern=782025

Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial

CompletedPH IIUniversity of Washingtonn=172025

A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).

CompletedPH IIIFondazione Italiana Linfomi - ETSn=5002024

Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)

CompletedPH IIMerck Sharp & Dohme LLCn=1462024

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20032022
Most influential

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

The New England journal of medicine · 2017 · 2,620 cites

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

The New England journal of medicine · 2003 · 1,909 cites

Estimating the global burden of Epstein-Barr virus-related cancers.

Journal of cancer research and clinical oncology · 2022 · 216 cites
Recent papers

Estimating the global burden of Epstein-Barr virus-related cancers.

Journal of cancer research and clinical oncology · 2022 · 216 cites

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

The New England journal of medicine · 2017 · 2,620 cites

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

The New England journal of medicine · 2003 · 1,909 cites
Major research themes1
Cystectomy1
Journals, researchers & institutions
Top journals
  • The New England journal of medicine2
  • Journal of cancer research and clinical oncology1
Leading researchers
  • Vogelzang NJ2
  • Bajorin DF1
  • Bellmunt J1
  • Burrows SR1
  • Choueiri TK1
  • Climent MA1
  • Crawford ED1
  • Culine S1
Leading institutions
free-text, unnormalised
  • Australian Institute of Tropical Health and Medicine1
  • Centre for Molecular Therapeutics1
  • Centre for Tropical Bioinformatics and Molecular Biology1
  • From Dana-Farber Cancer Institute1
  • M.D. Anderson Cancer Center1
  • QIMR Berghofer Medical Research Institute1

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Doxorubicin

Studied across 12 of the same disease areas as Vinblastine in the shared literature.

12 shared diseases2 shared papers
Bleomycin

Studied across 9 of the same disease areas as Vinblastine in the shared literature.

9 shared diseases1 shared paper
Dacarbazine

Studied across 9 of the same disease areas as Vinblastine in the shared literature.

9 shared diseases1 shared paper
Cisplatin

Studied across 7 of the same disease areas as Vinblastine in the shared literature.

7 shared diseases1 shared paper
Pembrolizumab

Studied across 6 of the same disease areas as Vinblastine in the shared literature.

6 shared diseases1 shared paper
Docetaxel

Studied across 5 of the same disease areas as Vinblastine in the shared literature.

5 shared diseases1 shared paper
Paclitaxel

Studied across 4 of the same disease areas as Vinblastine in the shared literature.

4 shared diseases1 shared paper
Methotrexate

Studied across 3 of the same disease areas as Vinblastine in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials